New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
10:53 EDTXOMAXOMA price target raised to $10 from $8 at Canaccord
Canaccord raised its price target for XOMA shares to $10 from $8 despite the erosive osteoarthritis of the hand trial failure. The firm said the setting was never part of its model and that its raised target reflects the pyoderma gangrenosum data. Canaccord reiterates a Buy rating on XOMA.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for XOMA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use